NICE does not recommend Opdivo (nivolumab) as a treatment for squamous NSCLC- BMS
The National Institute for Health and Care Excellence (NICE) in draft guidance has not recommended Opdivo (nivolumab) from BMS as a cost effective treatment for adult patients with locally advanced squamous NSCLC whose disease has progressed after prior chemotherapy. This rejection was made despite an offer of discount by BMS. Opdivo had shown in the CHECKMATE- 017 trial that 42% of patients with advanced squamous NSCLC were still alive at one year compared to 24% of those treated with docetaxel. The guidance is now for consultation.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins